Bodei, Lisa http://orcid.org/0000-0001-6930-7383
Herrmann, Ken
Schöder, Heiko
Scott, Andrew M.
Lewis, Jason S. http://orcid.org/0000-0001-7065-4534
Article History
Accepted: 20 May 2022
First Online: 20 June 2022
Competing interests
: L.B. has acted as a consultant and/or speaker for AAA-Novartis, Clovis Oncology, Iba, ITM and MTTI and received research funding from AAA-Novartis. K.H. has received personal fees from Adacap, Aktis Oncology, Amgen, Bayer, BTG, Curium, Endocyte, GE Healthcare, IPSEN, Pharma15, Novartis, Siemens Healthineers, SIRTEX, Theragnostics and YMabs; has received non-financial support from ABX and Sofie Biosciences and has received research funding from BTG. A.M.S. has acted as a consultant of Imagion Bio and ImmunOs; has received research funding from AbbVie, AVID, Cyclotek, Curis; has recevied research funding from AVID, Adalta, EMD Serono, Fusion, Humanigen, ITM, Merck, Medimmune, Telix Pharmaceuticals and Theramyc, and is a co-founder of Certis Therapeutics and Paracrine Therapeutics. J.S.L. has acted as an adviser of Boxer, Clarity Pharmaceuticals, Curie Therapeutics, Earli, Evergreen Theragnostics, Telix Pharmaceuticals, TPG Capital and Varian Medical Systems; is a co-inventor on technologies licensed to Diaprost, Daiichi Sankyo, Elucida Oncology, Macrocyclics and Samus Therapeutics; and is the co-founder of, and holds equity in, pHLIP and Sharp RTx. H.S. declares no competing interests.